Ernexa Therapeutics Inc.
ERNAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeErnexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. With a market capitalization of $3.4M, it sits in micro-cap territory. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
Market Cap
$3.4M
Beta
2.65
P/E (TTM)
—
P/E (Fwd)
-0.22
EPS (TTM)
$-13.56
EPS (Fwd)
$-9.60
ROE
-320.7%
ROA
-105.6%
Cash
$5.0M
Total Debt
$349,000
Free CF
-$5.9M
52W Change
-93.3%
Annual Financials
Cash vs Debt
Where ERNA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ERNA finished 64.07% below its 150-day moving average ($5.51) and 77.19% below its 200-day moving average ($8.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ERNA overbought or oversold?
At the October 20, 2026 close, ERNA's RSI(14) was 18.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Ernexa Therapeutics Inc. holds $5.0M in cash against $349K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$5.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -320.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, ERNA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, ERNA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Ernexa Therapeutics Inc.'s trajectory.